New research suggests that individuals who consistently carry Staphylococcus aureusin their noses have other nasal microbial community features that are distinct from those found in individuals without persistent S. aureus colonization.

Original from: genomeweb JP Morgan, BTIG, and Jefferies announced separately Monday that they have initiated coverage of molecular diagnostics firm BillionToOne. JP Morgan initiated coverag..

Original from: genomeweb Circular Genomics announced Monday that it raised $15 million in a Series A financing round led by Mountain Group Partners. The funds will support the development ..

Original from: businesswire In honour of World AIDS Day 2025, AIDS Healthcare Foundation (AHF) UK will host two community events to emphasize that the work to end HIV/AIDS is not over. The first commemor..

Cardiologists and primary-care physicians at a Midwest hospital system are using a polygenic risk score (PRS) to identify patients at risk for heart attacks who could benefit from more aggressive treatment.

Myriad Genetics, Clairity, and MagView said on 25 Nov that they have integrated their products to improve personalized breast cancer risk assessment.

Bengaluru-based deep-tech startup Morphle Labs has raised USD 5 million in a Series A round led by Inflexor Ventures to expand its physical AI-based automation systems for cancer diagnostics.

India has taken a significant step forward in the field of immunology with the launch of its first dedicated complement testing laboratory, designed to improve the diagnosis of complex autoimmune and inflammatory diseases.

The US Food and Drug Administration on Tuesday released a proposal to reclassify companion diagnostic assays from Class III medical devices to Class II devices.

The College of American Pathologists (CAP) on Monday released guidelines for accurate diagnosis of amyloidosis, emphasizing the importance of identifying subtypes of the rare disease caused by hereditary mutations that can be targeted for treatment.

Original from: CBS42 Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, tod..

3.2 The Growing Importance of Blood Coagulation Testing Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, ..

Original from: Agilent Fourth-quarter fiscal year 2025 · Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reporte..

GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.

Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1tn market valuation, a sharp turnaround from this summer when its stock was hit by disappointing results for a new obesity pill.

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.

Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

Sapphiros today announced a strategic supply and manufacturing option agreement with Roche that will grant exclusive rights to lateral flow technology manufacturing capacity to at least 1 billion tests annually from Sapphiros' extreme volume manufacturing process installed in the UK. The reel-to-reel manufacturing capability of Sapphiros can produce up to 5 billion diagnostics per year.

Abbott Laboratories is nearing a potential acquisition of cancer screening company Exact Sciences Corp., people familiar with the matter said, in what could be the biggest deal of the year in the global health-care sector.

Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.